Quantification of Tumor-Specific T Lymphocytes with the ELISPOT Assay

Journal of Immunotherapy

Volumn 23, Issue 3, 2000, Pages 289-295

  Schmittel, Alexander ^a   Keilholz, Ulrich ^a   Thiel, Eckhard ^a   Scheibenbogen, Carmen ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Cancer; ELISPOT assay; Peptide; T cells; Vaccine

Indexed keywords

CYTOKINE; HLA ANTIGEN CLASS 1; TUMOR ANTIGEN;

ANTIGEN PRESENTING CELL; CANCER; CONTROLLED STUDY; CYTOKINE RELEASE; HUMAN; IMMUNOTHERAPY; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; VACCINATION;

ANTIGENS, NEOPLASM; CANCER VACCINES; CHROMIUM; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MONITORING, IMMUNOLOGIC; NEOPLASMS; SENSITIVITY AND SPECIFICITY; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0034033763     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-200005000-00001     Document Type: Review

References (50)

1. Marchand M, Weynants P, Rankin E, et al. Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int J Cancer 1995; 63:883-5.
2. Jäger E, Bernhard H, Romero P, et al. Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: implications for tumor vaccines with melanoma-associated antigens. Int J Cancer 1996; 66:162-9.
3. Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nature Med 1998; 4:328-32.
4. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for treament of patients with metastatic melanoma. Nature Med 1998; 4:321-7.
5. Romero P, Cerottini J-C, Waanders GA. Novel methods to monitor antigen-specific cytotoxic T-cell responses in cancer immunotherapy. Mol Med Today 1998; 4:305-12.
6. Salgaller ML. Monitoring of cancer patients undergoing active or passive immunotherapy. J Immunother 1997; 20:1-14.
7. Ullman KS, Northrop JP, Verweij CL, Crabtree GR. Transmission of signals from the T lymphocyte antigen receptor to the genes responsible for cell proliferation and immune function: the missing link. Annu Rev Immunol 1990; 8:421-52.
8. Cantrell D. T cell antigen receptor signal transduction pathways. Annu Rev Immunol 1996; 14:259-74.
9. Berke G. The CTL's kiss of death. Cell 1995; 81:9-12.
10. Valitutti S, Lanzavecchia A. Serial triggering of TCRs: a basis for the sensitivity and specificity of antigen recognition. Immunol Today 1997; 6:299-304.
11. Harding CV, Unanue ER. Quantitation of antigen-presenting cell MHC class II/peptide complexes necessary for T-cell stimulation. Nature 1990; 346:574-6.
12. Brunner KT, Mauel J, Cerottini JC, Chapus B. Quantitative assay of the lytic action of immune lymphoid cells on 51Cr-labelled allogenic target cells in vitro; inhibition by isoantibodies and by drugs. Immunolology 1968; 14:181-96.
13. Spaeny-Dekking EH, Hanna WL, Wolbink AM, et al. Extracellular granzymes A and B in humans: detection of native species during CTL responses in vitro and in vivo. J Immunol 1998; 160:3610-16.
14. Hecht TT, Longo DL, Matis LA. The relationship between immune interferon production and proliferation in antigen-specific MHC-restricted T cell lines and clones. J Immunol 1983; 131:1049-55.
15. Mayer S, Scheibenbogen C, Lee KH, et al. A sensitive proliferation assay to determine the specific T cell response against HLA-A2.1-binding peptides. J Immunol Methods 1996; 197:131-7.
16. Hom SS, Schwarzentruber DJ, Rosenberg SA, Topalian SL. Specific release of cytokines by lymphocytes infiltrating human melanomas in response to shared melanoma antigens. J Immunother 1993; 13:18-30.
17. Steger GG, Pierce WC, Figlin R, et al. Patterns of cytokine release of unselected and CD8-selected renal cell carcinoma tumor-infiltrating lymphocytes (TIL). Evidence for enhanced specific killing of tumor necrosis factor-secreting/IL-6 nonsecreting TIL in vitro and correlation with complete response in vivo. Clin Immunol Immunopathol 1994; 72:237-47.
18. Tanguay S, Killion JJ. Direct comparison of ELISPOT and ELISA-based assays for detection of individual cytokine-secreting cells. Lymphokine and Cytokine Research 1994; 4:259-63.
19. Czerkinsky CC, Nielsson LA, Nygren H, Ouchterlony O, Tarkowski A. A solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells. J Immunol Methods 1983; 65:109-21.
20. Czerkinsky CC, Andersson G, Ekre HP, et al. Reverse ELISPOT assay for clonal analysis of cytokine production. Enumeration of gamma-interferon secreting cells. J Immunol Methods 1988; 110:29-36.
21. elGhazali GE, Paulie S, Andersson G, et al. Number of interleulin-4-and interferon-gamma-secreting human T cells reactive with tetanus toxoid and the mycobacterial antigen PPD or phytohemagglutinin: distinct response profiles depending on the type of antigen used for activation. Eur J Immunol 1993; 23:2740-5.
22. Merville P, Pouteil-Noble C, Wijdenes J, Potaux L, Touraine JL, Banchereau J. Detection of single cells secreting IFN-gamma, IL-6, and IL-10 in irreversible rejected human kidney allografts, and their modulation by IL-2 and IL-4. Transplantation 1993; 55:639-46.
23. Nordstrom I, Ferrua B. Reverse ELISPOT assay for clonal analysis of cytokine production. II. Enumeration of interleukin-1-secreting cells amplified (avidin-biotin anti-peroxidase) assay. J Immunol Methods 1992; 150:199-206.
24. Herr W, Schneider J, Lohse AW, et al. Detection and quantification of blood-derived CD8-T lymphocytes secreting TNFa in response to HLA-A2.1-binding melanoma and viral peptide antigens. J Immunol Methods 1996; 191:131-43.
25. Schmid DS, Thieme ML, Gary Jr, HE Reeves WC. Characterization of T cell response to herpes simplex virus type 1 (HSV-1) and herpes simplex virus type 2 (HSV-2) using a TNF-beta ELISPOT cytokine assay. Arch Virol 1997; 142:1659-71.
26. Medhat A, Shehata M, Bucci K, et al. Increased interleukin-4 and interleukin-5 production in response to Schistosoma haematobium adult worm antigens correlates with lack of reinfection after treatment. J Infect Dis 1998; 178:512-19.
27. + T cells using an ELISPOT assay. J Immunol Methods 1995; 181:45-54.
28. Schmittel A, Keilholz U, Scheibenbogen C. Evaluation of the interferon-γ ELISPOT-assay for quantification of peptide-specific T lymphocytes from peripheral blood. J Immunol Methods 1997; 210:167-74.
29. Cui Y, Chang LJ. Computer-assisted, quantitative cytokine enzyme-linked immunospot analysis of human immune effector cell function. Biotechniques 1997; 22:1146-9.
30. + T lymphocytes producing tumor necrosis factor a spots in response to peptide antigens. J Immunol Methods 1997; 203:141-52.
31. Yi Q, österborg A, Bergenbrant S, Mellstedt H, Holm G, Lefvert AK. Idiotype-reactive T-cell subsets and tumor load in monoclonal gammopathies. Blood 1995; 86:3043-9.
32. Scheibenbogen C, Lee K-H, Stevanovic S, et al. Analysis of the T cell response to tumor and viral peptide antigens by an IFN-γ-ELISPOT assay. Int J Cancer 1997; 71:932-6.
33. Scheibenbogen C, Schmittel A, Keilholz U, et al. Phase II trial of vaccination with tyrosinase peptides and GM-CSF in melanoma. J Immunother. in press, 2000.
34. Lewis JJ, Janetzki S, Wang S, et al. Phase I trial of vaccination with tyrosinase peptide plus QS-21 in melanoma (Abstract 1650). J Clin Oncol 1998;17.
35. + memory T cells. J Exp Med 1997; 186:859-65.
36. Scheibenbogen C, Lee K-H, Mayer S, et al. A sensitive ELISPOT assay for detection of CD8-T-lymphocytes specific for HLA class I binding peptide epitopes derived from influenza proteins in the blood of healthy donors and melanoma patients. Clin Cancer Res 1997; 3:221-6.
37. Schmittel A, Keilholz U, Max R, Thiel E, Scheibenbogen C. Induction of tyrosinase-reactive T cells by the treatment with dacarbacin, cisplatin, interferon-alpha—interleukin-2 in patients with metastatic melanoma. Int J Cancer 1999; 80:39-43.
38. + T cells that can synthesize type I cytokine. Cancer Res 1998; 58:1363-6.
39. Brossart P, Bevan MJ. Selective activation of Fas/Fas ligand-mediated cytotoxicity by a self peptide. J Exp Med 1996; 183:2449-58.
40. + T cell responses to MAGE-3 and Melan A/MART-1 by immunization to a polyvalent melanoma vaccine. Int J Cancer 1997; 72:972-6.
41. Rönnelid J, Klareskog L. A comparison between ELISPOT methods for the detection of cytokine producing cells: greater sensitivity and specificity using ELISA plates as compared to nitrocellulose membranes. J Immunol Methods 1997; 200:17-26.
42. Weber JS, Spears L, Jeffery G, et al. A phase I trial of a MART-1 HLA-A2 restricted peptide vaccine for resected high risk melanoma (Abstract 1676). J Clin Oncol 1998;17.
43. Pass HA, Schwarz SL, Wunderlich JR, Rosenberg SA. Immunization of patients with melanoma peptides vaccines: immunologic assessment using the ELISPOT assay. Cancer J Sci Am 1998; 4:316-23.
44. Mammi C, Herr W, Del Bello D, et al. Analysis by ELISPOT assay of CTL precursors specific for HLA-A2.1-binding ErbB-2 peptides in breast cancer patients (Abstract 62). Proc Am Assoc Cancer Res 1998;39.
45. Salgaller ML, Lodge PA, Tjoa BA, et al. Monitoring of prostate-specific membrane antigen (PSMA)-specific immune responses and prostate markers in a phase II clinical trial with patients infused with dendritic cells pulsed with PSMA-derived peptides (Abstract 1187). Proc Am Assoc Cancer Res 1998;39.
46. Valone FH, Small EJ, Whisenant S, et al. Immunotherapy of hormone refractory prostate cancer with antigen-pulsed dendritic cells: a phase I/II trial (Abstract 1334). J Clin Oncol 1998;17.
47. Bergenbrant S, Yi Q, österborg A, et al. Modulation of anti-idiotypic immune response by immunization with autologous M-component protein in multiple myeloma patients. Br J Haematol 1996; 92:840-6.
48. + and CD4-specific T-cell responses. Blood 1998; 91:2459-66.
49. Hanke T, Blanchard TJ, Schneider J, et al. Immunogenicities of intravenous and intramuscular administrations of modified vaccinia virus Ankara-based multi-CTL epitope vaccine for human immunodeficiency virus type 1 in mice. J Gen Virol 1998; 70:83-90.
50. Kukulin N, Daheshia M, Karem K, Manickan E, Rouse BT. Induction of mucosal immunity against herpes simplex viris by plasmid DNA immunization. J Virol 1997; 74:3138-45.